10X Genomics, Inc.

10X Genomics, Inc. is a biotechnology company specializing in genomic technology platforms that enhance biological research and improve human health through innovative solutions. Founded in 2012, 10X Genomics, Inc. is headquartered in Pleasanton, US.

The company develops technology that streamlines genomic analysis. Co-founded by Ben Hindson and Serge Saxonov, 10X Genomics has raised USD 440. 00 mn in total, with its most recent funding round being a Private Placement/Follow on in September 2019, amounting to USD 440. 00 mn.

10X Genomics specializes in innovative genomic technology platforms that enhance biological research and advance human health. The company’s core products include the Chromium Single Cell platform, which allows researchers to perform transcriptomic profiling of up to a million single cells, revealing cellular diversity and characteristics on a granular level. Additionally, the Visium Spatial platform enables whole transcriptome analysis of fresh and fixed tissues while maintaining their morphological context, crucial for understanding disease mechanisms and cellular interactions. Their Xenium In Situ platform provides subcellular resolution mapping of RNA molecules within tissue sections.

These advanced tools are primarily designed for research institutions, pharmaceutical companies, and biotech firms, which utilize them to unlock insights into gene expression, cellular behavior, and drug development across various therapeutic areas. The company markets its products globally, targeting regions such as North America, Europe, and Asia. In the most recent fiscal year of 2024, 10X Genomics generated total revenue of USD 610. 79 mn and reported an EBITDA of USD -194.

56 mn. Revenue is generated mainly through the sale of genomic products and related services to research and clinical markets, structured as B2B engagements with institutions and academic partners. 10X Genomics plans to launch new products designed to further enhance its genomic technology offerings. The company aims to expand into new markets including Europe and Asia by the end of 2024.

The recent funding round of USD 440. 00 mn will be utilized to support these initiatives, particularly in advancing product development and expanding market reach. In September 2019, 10X Genomics raised USD 390 mn in an IPO, selling 10 million shares at USD 39 per share on the Nasdaq, followed by another sale of 4 million shares for USD 440 mn in 2020.